Aurinia Pharmaceuticals Inc. (AUPH)
Stock Price:
$15.16 USD
-0.04 (-0.26%)
Updated December 1, 9:42 AM EST - Market open
Key Info
| Market Cap |
3.83B |
| Revenue (ttm) |
117,000 |
| Net Income (ttm) |
-156.60M |
| Shares Out |
126.45M |
| EPS (ttm) |
-1.41 |
| PE Ratio |
n/a |
| Forward PE |
1,428.57 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 1 |
| Last Price |
$15.16 |
| Previous Close |
$15.20 |
| Change ($) |
-0.04 |
| Change (%) |
-0.26% |
| Day's Open |
14.64 |
| Day's Range |
15.02 - 15.18 |
| Day's Volume |
1,318,706 |
| 52-Week Range |
7.98 - 21.46 |
More Stats
| Market Cap |
3.83B |
| Enterprise Value |
3.45B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
126.45M |
| Float |
n/a |
| EPS (basic) |
-1.50 |
| EPS (diluted) |
-1.41 |
| FCF / Share |
-0.92 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.12M |
| Short Ratio |
4.45 |
| Short % of Float |
n/a |
| Beta |
0.87 |
| PE Ratio |
n/a |
| Forward PE |
1,428.57 |
| P/FCF Ratio |
n/a |
| PS Ratio |
32,768.80 |
| PB Ratio |
4.44 |
| Revenue |
117,000 |
| Operating Income |
-120.21M |
| Net Income |
-156.60M |
| Free Cash Flow |
-102.54M |
| Net Cash |
383.74M |
| Net Cash / Share |
1.52 |
| Gross Margin |
-44,912.82% |
| Operating Margin |
-102,746.15% |
| Profit Margin |
-133,849.60% |
| FCF Margin |
-87,641.03% |
| ROA |
-22.38% |
| ROE |
-59.93% |
| ROIC |
-254.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (9)
| Buy |
8 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$23.03*
(51.91% upside)
Low
17.3
Current: $15.16
High
30.0
Target: 23.03
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.32 | 0.46 | 0.42 | 0.17 | 0.24 | 0.28 | 0.97 | 6.13 |
| Revenue Growth | -31.32% | 10.77% | 141.62% | -26.38% | -15.47% | -71.31% | -84.18% | - |
| Gross Profit | 0.32 | 0.46 | 0.42 | 0.17 | 0.22 | 0.24 | 0.97 | 6.08 |
| Operating Income | -85.24 | -56.33 | -46.87 | -25.03 | -23.71 | -16.65 | -6.57 | -9.69 |
| Net Income | -124 | -64.12 | -70.79 | -23.30 | -18.61 | -19.42 | -2.66 | -9.69 |
| Shares Outstanding | 85.50 | 84.05 | 52.81 | 32.29 | 31.82 | 31.37 | 31.37 | - |
| Earnings Per Share | -1.33 | -0.76 | -0.92 | -0.66 | -0.58 | -0.67 | -0.42 | -2.73 |
| Operating Cash Flow | -63.46 | -51.61 | -41.17 | -18.71 | -17.77 | -16.91 | -4.62 | -6.51 |
| Capital Expenditures | -0.10 | -0.08 | -0.03 | -0.01 | -0.05 | -0.09 | -0.04 | - |
| Free Cash Flow | -63.56 | -51.69 | -41.19 | -18.72 | -17.82 | -16.99 | -4.66 | -6.51 |
| Cash & Equivalents | 306 | 126 | 173 | 39.65 | 15.75 | 32.70 | 1.82 | 0.19 |
| Total Debt | - | - | - | - | - | - | 1.32 | 1.71 |
| Net Cash / Debt | 306 | 126 | 173 | 39.65 | 15.75 | 32.70 | 0.50 | -1.52 |
| Assets | 327 | 146 | 190 | 57.00 | 33.57 | 52.38 | 23.17 | 4.16 |
| Liabilities | 53.17 | 33.29 | 24.10 | 21.05 | 13.60 | 18.51 | 9.85 | 6.28 |
| Book Value | 274 | 113 | 166 | 35.95 | 19.96 | 33.87 | 13.31 | -2.12 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aurinia Pharmaceuticals Inc. |
| Country |
Canada |
| Employees |
62 |
| CEO |
Peter S. Greenleaf |
Stock Information
| Ticker Symbol |
AUPH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AUPH |
| IPO Date |
January 26, 1999 |
Description
Aurinia Pharmaceuticals, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.